That which is claimed is:

1. Use of an intravenous narcotic emulsion formulation in the manufacture of a medicament for treating a subject for cancer pain, wherein the emulsion formulation comprises:

Fentanyl as the only active agent;

oil;

water;

a surfactant; and

an emulsification enchancer.

2. The use according to Claim 1, wherein said fentanyl is present in an amount ranging from 0.1 to 10 mg/ml.

3. The use according to Claims 1 or 2, wherein said oil is present in an amount ranging from 0.05 to 200 mg/ml.

4. The use according to Claims 1, 2 or 3, wherein said ~~surfacant~~ surfactant is chosen from egg-yolk phospholipid or soybean phospholipid.

5. The use according to any of Claims 1 to 4, wherein said emulsification enhancer is oleic acid.

6. The use according to any of Claims 1 to 5, wherein said emulsion formulation further comprises glycerin.

7. The use according to any of Claims 1 to 6, wherein said emulsion formulation exhibits comparable efficacy as compared to ~~a FENTANEST™~~ an aqueous 0.1 mg/2 ml fentanyl citrate injection formulation.

8. The use according to any of Claims 1 to 7, wherein said emulsion formulation exhibits reduced central nervous system mediated side effects as compared to ~~a FENTANEST™~~an aqueous 0.1 mg/2 ml fentanyl citrate injection formulation.

9. A kit comprising an intravenous emulsion formulation comprising:
fentanyl as the only active agent;
oil;
water;
a surfactant and
an emulsification enhancer.

~~10. The use according to Claim 1, wherein fentanyl is the only active agent.~~

~~11. The kit according to Claim 9, wherein fentanyl is the only active agent.~~